You are here: Industry Insights > VBL

News List

VBL Announces Patient Dosing of Recurrent Glioblastoma Multiforme Trial americanpharmaceuticalreview
March 04, 2021
VBL Therapeutics announced patient dosing has been initiated in a Phase 2 clinical trial investigating ofranergene obadenovec (VB-111) for the treatment of recurrent glioblastoma multiforme (rGBM).
Data Safety Monitoring Committee Green Lights Ovarian Cancer Study americanpharmaceuticalreview
February 24, 2021
VBL Therapeutics announced the results of the independent Data Safety Monitoring Committee (DSMC) pre-planned review of the ongoing OVAL Phase 3 registration enabling study of VB-111 in recurrent ovarian cancer.
VBL Therapeutics Treats First Patient in Study of VB-201 in COVID-19 Patients americanpharmaceuticalreview
February 03, 2021
VBL Therapeutics announced the dosing of the first patient in a randomized controlled Phase 2 study of the Company’s proprietary investigational oral immune-modulator molecule, VB-201 for the treatment of COVID-19.
VBL Enrolls First Patients in VB-111 Trial for Metastatic Colorectal Cancer americanpharmaceuticalreview
September 18, 2020
VBL Therapeutics announced the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.